MIAMI--(BUSINESS WIRE)--Nov. 15, 2005--DOR BioPharma, Inc. (AMEX:DOR) (“DOR” or the “Company”), announced today that following written communications and meetings with the FDA and with the comparable regulatory authorities of the German, French and UK governments, it has established an expanded strategy for the submission of a New Drug Application (NDA) and Marketing Authorization Application (MAA) for orBec(R) for the treatment of intestinal Graft-versus-Host disease (“iGVHD”).
